Related Experiment Videos
Neutralizing antibodies in gene-defective hosts
Ghislain Opdenakker1, Philippe E Van den Steen, Geneviève Laureys
1Rega Institute for Medical Research, Laboratory of Immunobiology, University of Leuven, Minderbroedersstraat 10, Belgium. ghislain.opdenakker@rega.kuleuven.ac.be
Trends in Immunology
|January 28, 2003
Summary
In individuals with genetic defects, the body may produce neutralizing antibodies against nondefective gene products. This risk increases with protein substitution or gene therapy, impacting treatment outcomes.
Area of Science:
- Immunology
- Genetics
- Molecular Biology
Background:
- A complete gene defect in a host with a normal immune system can lead to the nondefective gene product becoming immunogenic.
- Neutralizing antibodies against the respective protein can arise spontaneously or after immunization in patients and animal models.
Purpose of the Study:
- To compare and exemplify genetic and immunological contexts leading to "neutralizing and generated by gene defect" (NAGGED) antibodies.
- To outline implications and solutions for therapeutic strategies concerning NAGGED antibodies.
Main Methods:
- Review of existing literature and case studies.
- Comparison of genetic and immunological factors.
- Analysis of animal models (e.g., knockout mice).
Main Results:
- Patients with X-linked or homozygous autosomal gene defects are at risk of developing neutralizing antibodies.
- The risk is particularly elevated after protein substitution or gene therapy.
- Identified various contexts leading to NAGGED antibody formation.
Conclusions:
- Understanding the mechanisms of NAGGED antibody generation is crucial for managing patients with genetic disorders.
- Therapeutic strategies, including protein substitution and gene therapy, must consider the potential for immunogenicity.
- Developing solutions to mitigate or prevent NAGGED antibody formation is essential for improving treatment efficacy.